Parkinson disease Cannabidiol enriched cannabis extraction product, Inflammatory marker, Parkinson disease, Cannabidiol, Cognitive function
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The inclusion criteria were age more than 40 years, diagnosis of PD using the UK PD Society Brain Bank diagnostic criteria, Hoehn and Yahr Stages 1 to 3, stable dosage of PD medications for at least 3 months, and willingness of patients and caregivers to participate in the study.
Exclusion criteria
Exclusion criteria: Patients were excluded if they had dementia, schizophrenia, or other psychotic disorders; kidney or liver disease; serum alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels >3 times the upper limit of the normal range; or a history of high-risk behavior related to substance abuse, including nicotine, cannabis, and alcohol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Delay Recall 12 weeks Thai Montreal Cognitive Assessment delayed recall | — |
Secondary
| Measure | Time frame |
|---|---|
| Inflammatory markers 12 weeks ( white blood cell counts, erythrocyte sedimentation rate, C- reactive protein, ferritin level),Disease severity 12 weeks UPDRS III,Anxiety and depression 12 weeks HADS,Cognitive function 12 weeks MOCA ,LAB 12 weeks Renal and liver functions,side effect 12 weeks side effect,CBD level 12 weeks Serum CBD | — |
Countries
Thailand
Contacts
Buriram Hospital